New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Viridian Therapeutics, Inc.
VRDN
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

2B

Biotechnology

Next Earning date - 11 Nov 2024

2B

Biotechnology

Next Earning date - 11 Nov 2024

23.05USD
Shape-0.31 ( -1.33%)
favorite-chart

Relative Strenght

8
favorite-chart

Volume Buzz

-65%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

9%

Quote Panel

Shape
Updated October 26, 2024
1W -6.19 % 1M -1.20 % 3M 33.31 % 1Y 86.19 %

Key Metrics

Shape
  • Market Cap

    1.76B


  • Shares Outstanding

    76.36M


  • Share in Float

    68.00M


  • Dividende

    0


  • Earning Date

    11 Nov 2024


  • Price Target

    23.05


  • Average Volume

    1.44M


  • Beta

    1.091


  • Range

    11.4-25.385


  • Industry

    Biotechnology


  • Website

    https://www.viridiantherapeutics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

6193.36x

P/S Ratio

2.82x

P/B Ratio

0.0

Debt/Equity

-79185.8%

Net Margin

$-4.3

EPS

How VRDN compares to sector?

P/E Ratio

Relative Strength

Shape

VRDN

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$251K

Shape249%

2025-Revenue

$4.21

Shape-313%

2025-EPS

$251K

Shape100%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Wolfe Research

initialise

Previous: Not converted

2024-06-10

Now: Outperform

Goldman Sachs

initialise

Previous: Not converted

2024-06-06

Now: Buy

B. Riley

downgrade

Previous: Buy

2024-05-09

Now: Neutral

Needham

initialise

Previous: Not converted

2022-12-19

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.86
vs -1.25

Q4.22

arrow
arrow

N/A

-1.13
vs -1.32

Q1.23

arrow
arrow

N/A

-1.61
vs -0.98

Q2.23

arrow
arrow

N/A

-1.27
vs -1.06

Q3.23

arrow
arrow

N/A

-1.09
vs -0.86

Q4.23

arrow
arrow

N/A

-1.35
vs -1.13

Q1.24

arrow
arrow

N/A

-0.79
vs -1.61

Q2.24

arrow
arrow

N/A

-1.02
vs -1.27

Q3.24

arrow
arrow

N/A

-1.06
vs -1.09

Q4.24

arrow
arrow

N/A

-1.03
vs -1.35

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+475%

1.2M  vs 208K

Q4.22

arrow
arrow

-51%

105K  vs 214K

Q1.23

arrow
arrow

-55%

98K  vs 216K

Q2.23

arrow
arrow

-72%

72K  vs 256K

Q3.23

arrow
arrow

-94%

72K  vs 1.2M

Q4.23

arrow
arrow

-31%

72K  vs 105K

Q1.24

arrow
arrow

-27%

72K  vs 98K

Q2.24

arrow
arrow

NA

72K  vs 72K

Q3.24

arrow
arrow

+26%

91K  vs 72K

Q4.24

arrow
arrow

+21%

87.1K  vs 72K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-7%

-0.07
vs -0.21

Q4.22

arrow
arrow

-11%

-0.11
vs -0.07

Q1.23

arrow
arrow

-19%

-0.19
vs -0.11

Q2.23

arrow
arrow

-17%

-0.17
vs -0.19

Q3.23

arrow
arrow

-17%

-0.17
vs -0.17

Q4.23

arrow
arrow

-15%

-0.15
vs -0.17

Q1.24

arrow
arrow

-8%

-0.08
vs -0.15

Q2.24

arrow
arrow

-12%

-0.12
vs -0.08

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

108

108
vs 88

23%

Q4.22

arrow
arrow

128

128
vs 108

19%

Q1.23

arrow
arrow

145

145
vs 128

13%

Q2.23

arrow
arrow

142

142
vs 145

-2%

Q3.23

arrow
arrow

126

126
vs 142

-11%

Q4.23

arrow
arrow

139

139
vs 126

10%

Q1.24

arrow
arrow

143

143
vs 139

3%

Q2.24

arrow
arrow

146

146
vs 143

2%

Earnings Growth

Latest News

VRDN

schaeffersresearch.com

10 hours ago